格隆汇1月8日｜默沙东(MRK.US)跌2.6%，报98.39美元。消息面上，Truist Securities称，2024年生物制药行业在并购方面令人失望，该行业需要更大/更多的并购交易才能复苏。Truist将默沙东公司的评级从“买入”下调至“持有”，目标价从130美元下调至110美元。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：郭明煜

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.